

Contact: Charles Triano
Vice President – Investor Relations
Forest Laboratories, Inc.
Tel: (212) 224-6714
charles.triano@frx.com

Sabrina Martucci Johnson, CFO, CBO, Ex. VP
Mary Gieson, Investor Relations
Cypress Bioscience, Inc.
Tel: (858) 452-2323
Mgieson@cypressbio.com

**FOREST LABORATORIES AND CYPRESS BIOSCIENCE TO HOST WEBCAST
TO DISCUSS CLINICAL DATA PRESENTATIONS FOR MILNACIPRAN**

NEW YORK and SAN DIEGO ---November 2, 2007 - Forest Laboratories, Inc. (NYSE: FRX), and Cypress Bioscience, Inc. (NASDAQ: CYPB) will host a webcast to discuss milnacipran clinical data being presented at the American College of Rheumatology annual conference. The webcast, which will include a slide presentation, will occur on November 8, 2007 at 10:00am EST. Representing Forest Laboratories will be Dr. Lawrence Olanoff, President and Chief Operating Officer of Forest and representing Cypress Bioscience will be Dr. Jay Kranzler, Chairman and Chief Executive Officer of Cypress. Also presenting on the webcast will be Dr. Daniel J. Clauw and Dr. Philip Mease, two milnacipran study investigators that will provide an overview of fibromyalgia syndrome and the current challenges faced by both patients and physicians in managing this complex disease, as well as discuss the milnacipran data findings being presented at ACR.

The webcast can be accessed at the URL: <http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=83198&eventID=1686016>

The webcast will also be available on the Forest Laboratories and Cypress Bioscience websites at www.frx.com and www.cypressbio.com.

A replay of the conference call will be available until December 8, 2007 on both websites.

About Milnacipran:

Milnacipran is a unique dual-reuptake inhibitor, which preferentially blocks the reuptake of norepinephrine with higher potency than serotonin, two neurotransmitters known to play an essential role in regulating pain and mood. It has been approved for the treatment of depression in over 32 countries and has been used by more than 5 million patients during more than 10 years of commercial availability outside the U.S. Milnacipran is being developed for fibromyalgia in the United States market jointly by Forest and its licensor, Cypress Bioscience, Inc.

Sources: Forest Laboratories, Inc. and Cypress Bioscience, Inc.

###